GMR
The Original

BEYOND THE TUMOR: A PHILOSOPHICAL PERSPECTIVE ON HEAD AND NECK CANCER, HUMAN IDENTITY, AND THE FUTURE OF PRECISION ONCOLOGY

Vigneshwar M[1], Srinivasan M.K[2*]

[1]Department of Otorhinolaryngology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, 602105, Tamil Nadu, India. vigneshvicky2996@gmail.com
[2]Department of ENT, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Thandalam, Chennai 602 105, Tamil Nadu, India. kumarsri07021999@gmail.com

Abstract
Head and neck cancer (HNC) represents a unique intersection between complex tumor biology and profound human consequences. Unlike many other malignancies, HNC affects anatomical structures responsible for communication, swallowing, breathing, and facial identity, creating challenges that extend beyond disease control and survival. Although advances in molecular oncology have improved understanding and treatment of HNC, the disease remains a major clinical challenge due to biological heterogeneity, therapeutic resistance, and significant effects on quality of life. This review provides an integrated perspective on HNC by connecting cellular evolution, molecular mechanisms, patient experience, and future therapeutic strategies. The biological foundation of HNC development is explored through the concepts of disrupted cellular communication, genomic instability, clonal evolution, epigenetic plasticity, and tumor microenvironmental interactions. These evolutionary processes explain tumor heterogeneity, metastatic potential, and resistance to therapy. The review further examines the human dimension of HNC, emphasizing the effects of facial alteration, speech and swallowing impairment, stigma, psychological burden, and ethical challenges associated with balancing survival outcomes with functional preservation. Recent advances in precision oncology have shifted HNC management from anatomical classification toward molecularly guided approaches. Integration of genomic profiling, transcriptomics, microRNA-based biomarkers, liquid biopsy, artificial intelligence, and tumor ecosystem analysis provides opportunities for individualized diagnosis, treatment selection, and disease monitoring. Emerging therapeutic platforms, including immunotherapy, nanotechnology, regenerative medicine, and early molecular surveillance, represent promising strategies for transforming HNC care from reactive treatment toward preventive and predictive medicine. Ultimately, the future of HNC management requires a multidisciplinary framework that integrates molecular precision with human-centered care. Successful cancer medicine will depend not only on controlling tumor evolution but also on preserving communication, identity, dignity, and quality of life for every patient.

Keywords: Head and neck cancer; tumor evolution; cancer biology; tumor microenvironment; precision oncology; molecular biomarkers; liquid biopsy; immunotherapy; patient-centered medicine.

INTRODUCTION

Head and neck cancer (HNC) represents a heterogeneous group of malignancies arising from the lip, oral cavity, pharynx, larynx, nasal cavity, and salivary glands. Among these, head and neck squamous cell carcinoma (HNSCC) is the predominant histological subtype and is recognized as the sixth most common cancer worldwide, with more than 500,000 new cases reported annually. Major risk factors include tobacco exposure, alcohol consumption, and infection with high-risk human papillomavirus (HPV) [1]. Despite advances in diagnosis and treatment, HNC remains associated with substantial morbidity due to its effects on essential functions, including speech, swallowing, breathing, and facial appearance, thereby influencing both physical health and psychosocial well-being.

Molecular studies have demonstrated that HNSCC is not a single disease entity but comprises biologically distinct subgroups characterized by variations in gene expression patterns, genomic alterations, and molecular signatures that contribute to differences in tumor behavior and clinical outcomes [2]. These molecular changes interact with environmental and lifestyle factors, including tobacco, alcohol, dietary factors, and chemical exposures, influencing cancer initiation, progression, and metastatic potential [3]. Tobacco and alcohol represent the most established modifiable risk factors, with alcohol enhancing the carcinogenic effects of tobacco by increasing mucosal permeability and facilitating prolonged exposure to tobacco-derived carcinogens [4]. Furthermore, genetic susceptibility, socioeconomic factors, and behavioral patterns collectively contribute to individual variations in HNC risk and disease progression [5].

Unlike many other cancers, HNC affects anatomically visible and functionally critical regions of the body, resulting in significant alterations in appearance, communication, nutrition, and social interaction. Treatment-related consequences such as facial disfigurement, speech impairment, swallowing difficulties, xerostomia, and nutritional challenges can profoundly affect body image, emotional health, and overall quality of life [6]. Consequently, patients with HNC frequently experience higher levels of psychological distress, including depression, anxiety, fear of recurrence, and reduced social functioning, compared with individuals affected by other cancer types [7]. These challenges extend beyond patients to caregivers, who often experience considerable emotional and supportive burdens throughout the disease trajectory.

Recognition of the multidimensional impact of HNC has shifted the focus of oncology care from solely tumor control toward comprehensive survivorship-oriented approaches. Current clinical strategies emphasize the integration of rehabilitation, psychological support, nutritional management, and patient-reported outcomes alongside conventional treatment and disease surveillance [8,9]. Effective HNC management therefore requires a multidisciplinary approach involving oncologists, surgeons, speech and language therapists, nutritionists, psychologists, rehabilitation specialists, and caregivers to address both the biological complexity of the disease and the long-term functional and psychosocial needs of survivors [10].

2. The biological philosophy of cancer development: From cellular dysregulation to tumor evolution

Cancer development is not merely the uncontrolled proliferation of abnormal cells but represents a complex evolutionary process involving disruption of cellular regulation, genomic stability, and tissue homeostasis. In head and neck tissues, continuous exposure to carcinogens, viral infections, and chronic inflammatory stimuli promotes progressive alterations in cellular identity and behavior. Tumorigenesis therefore reflects the interaction between genetic alterations, epigenetic reprogramming, microenvironmental changes, and adaptive mechanisms that enable malignant cells to survive, proliferate, invade, and resist therapeutic interventions. Viewing cancer as an evolving biological system provides a framework for understanding tumor heterogeneity, progression, and treatment failure.

2.1. Disruption of cellular communication and loss of tissue homeostasis in cancer development

Multicellular organisms depend on coordinated cellular communication to regulate proliferation, differentiation, apoptosis, and tissue repair. Cancer arises when these regulatory networks become disrupted, allowing cells to acquire autonomous growth advantages and escape normal biological constraints. In head and neck squamous cell carcinoma (HNSCC), altered signaling pathways, including epidermal growth factor receptor (EGFR), PI3K/AKT/mTOR, JAK/STAT, and WNT pathways, contribute to abnormal interactions between tumor cells, stromal components, immune cells, and vascular networks, creating a microenvironment that supports tumor growth and invasion [1].

A central feature of HNSCC progression is the loss of genomic surveillance mechanisms. Tumor suppressor genes such as TP53, RB1, CDKN2A, and PTEN regulate cell cycle control, DNA repair, apoptosis, and cellular differentiation. Their inactivation promotes genomic instability, uncontrolled proliferation, and acquisition of aggressive tumor phenotypes [2]. However, tumor behavior is not determined solely by genetic alterations; rather, the interaction between molecular changes and the surrounding tumor microenvironment critically influences disease progression.

2.2. Mutation, clonal selection, and adaptive evolution in tumor progression

Cancer progression follows evolutionary principles in which genetic variation and environmental selection pressures determine the survival and expansion of malignant clones. Somatic mutations provide diversity within tumor populations, while selective pressures favor cells with advantageous traits, including enhanced proliferation, invasion, angiogenesis, immune evasion, and resistance to therapy [11]. This Darwinian model of tumor evolution explains how heterogeneous cancer cell populations emerge and why treatment-resistant subclones can develop during disease progression [12]. In HNSCC, genomic studies have revealed substantial molecular diversity between human papillomavirus (HPV)-positive and HPV-negative tumors, with distinct genetic alterations and biological behaviors. The variable mutational landscape among tumors highlights that HNSCC does not follow a single evolutionary pathway but develops through multiple molecular trajectories shaped by genetic background, environmental exposure, and tissue-specific factors.

2.3. Epigenetic reprogramming and phenotypic plasticity in cancer progression

Although genetic alterations provide the foundation for tumor evolution, epigenetic mechanisms enable cancer cells to adapt rapidly to changing environmental conditions. Recent cancer models recognize epigenetic reprogramming and phenotypic plasticity as key features that allow malignant cells to alter their identity, maintain stem-like properties, and survive therapeutic stress [13]. In HNSCC, epigenetic alterations, including DNA methylation changes, histone modifications, and chromatin remodeling, regulate genes involved in proliferation, differentiation, immune response, and metastasis. These mechanisms facilitate cellular plasticity, allowing tumor cells to transition between different phenotypic states in response to hypoxia, inflammation, and treatment pressure [14]. Epithelial–mesenchymal transition (EMT) and related plasticity programs are particularly important in promoting invasion, metastatic dissemination, and resistance to anticancer therapies [15].

2.4. Cancer as an evolutionary and ecological system: Implications for therapeutic resistance

The evolutionary perspective of cancer has transformed the understanding of tumor progression from a process of simple cellular destruction into a dynamic interaction between malignant cells and their surrounding ecosystem. Tumors undergo

continuous cycles of clonal expansion, diversification, and selection within the constraints imposed by the tissue microenvironment. These evolutionary patterns may occur through linear progression, branching evolution, or neutral evolutionary processes depending on tumor type and selective pressures [16].

Therapeutic interventions act as evolutionary forces by eliminating sensitive cancer populations while creating opportunities for resistant clones to expand. Therefore, intratumoral heterogeneity, microenvironmental adaptation, and ecological interactions among cancer cells contribute significantly to recurrence and treatment failure [16,17]. Understanding cancer through an evolutionary and ecological framework provides new opportunities for developing adaptive therapeutic strategies aimed at controlling tumor evolution rather than only targeting established tumor populations.

3. The Human impact of head and neck cancer: Identity, communication, and quality of life

HNC is distinct among solid malignancies because both the disease and its treatment directly affect anatomical structures essential for communication, respiration, swallowing, and facial appearance. Therefore, clinical outcomes cannot be assessed solely through survival and recurrence rates; functional preservation, psychosocial well-being, and quality of life are equally important determinants of successful cancer care. Alterations in facial appearance, voice, and swallowing function can profoundly influence self-perception, social interaction, and overall patient experience throughout survivorship (Figure 1).

3.1. Relationship between facial anatomy and personal identity

The face and neck represent critical components of human identity, social interaction, and emotional expression. Surgical resection, radiation therapy, and treatment-related functional impairments can result in changes in appearance and bodily perception that extend beyond physical disability, affecting self-esteem, confidence, and social participation. Patients with HNC often experience a complex process of adaptation involving diagnosis acceptance, coping with functional and aesthetic changes, and reconstruction of personal identity after treatment [18]. Consequently, management of HNC requires consideration of both oncological control and restoration of appearance and function. Reconstructive strategies, including surgical reconstruction and prosthetic rehabilitation, should be integrated into treatment planning because restoration of facial structure and function contributes significantly to psychological recovery and social reintegration [19].

3.2. Communication impairment and psychosocial consequences of functional loss

Functional impairments associated with oral cavity, laryngeal, and pharyngeal cancers significantly affect communication and social interaction. The oral cavity contributes to articulation, the larynx enables phonation, and the pharynx plays essential roles in swallowing and resonance. Loss of these functions can produce substantial emotional distress, social stigma, and reduced quality of life.

Studies evaluating stigma among HNC patients have identified speech difficulties, social concerns, and treatment-related regret as major contributors to psychosocial burden. Increased stigma has been associated with younger age, impaired body image, depression, reduced physical functioning, and decreased psychosocial well-being [20]. Among patients with laryngeal cancer, preservation of natural voice remains a major consideration during treatment decision-making. Many individuals consider voice preservation and the ability to communicate effectively as essential components of personal identity and social independence, influencing their preference for organ-preserving approaches despite potential differences in survival outcomes [21].

3.3. Ethical challenges in balancing survival and quality of life

Treatment decisions in HNC often involve complex ethical considerations, particularly when aggressive interventions may improve survival but compromise essential functions such as speech and swallowing. Laryngeal cancer represents a classic example of this dilemma, where patients and clinicians must balance oncological benefit against preservation of communication and quality of life. Utility-based studies have demonstrated that some individuals may prioritize functional preservation, such as maintaining natural voice, even when associated with reduced survival probability [22]. However, differences frequently exist between patient preferences and healthcare providers' perceptions of those preferences. Studies have shown that clinicians may underestimate the importance patients place on functional outcomes, highlighting the need for shared decision-making models that incorporate individual values, expectations, and quality-of-life priorities [23].

3.4. Reconstructive medicine as a component of functional and psychosocial recovery

Reconstructive approaches in HNC should be considered an essential component of comprehensive cancer treatment rather than merely an aesthetic intervention. Restoration of facial structures, speech, and swallowing function through microvascular free-flap reconstruction, prosthodontic rehabilitation, and functional restoration procedures contributes significantly to patient recovery and social reintegration [24]. Beyond physical restoration, psychological adaptation plays an important role in long-term survivorship. Patients may develop new coping mechanisms and altered perceptions of self following treatment, with appropriate psychosocial support facilitating acceptance and adjustment to post-treatment changes [25]. Thus, successful HNC care requires integration of oncological treatment, functional rehabilitation, reconstructive strategies, and psychological support to restore both biological health and personal identity.



Figure 1. The human impact of head and neck cancer: Identity, communication, and quality of life

4. Precision oncology in head and neck cancer: From conventional treatment to molecularly guided therapy

Traditional cancer treatment has largely relied on anatomical location, histological classification, and population-based treatment protocols. However, advances in molecular biology have revealed that head and neck squamous cell carcinoma (HNSCC) represents a biologically diverse group of tumors with distinct genomic, epigenetic, and microenvironmental characteristics. Precision oncology has therefore shifted the therapeutic paradigm from a generalized "one disease–one treatment" approach toward individualized strategies based on the molecular profile of each tumor.

4.1. Molecular classification of head and neck cancer: Moving beyond anatomical diagnosis

The development of large-scale genomic studies has fundamentally changed the understanding of HNSCC biology. Comprehensive genomic characterization by The Cancer Genome Atlas (TCGA) demonstrated that HNSCC comprises multiple molecular subtypes rather than a single disease entity. HPV-positive tumors exhibit distinct biological features compared with HPV-negative tumors, while HPV-negative HNSCC can be further classified based on genomic alterations, copy-number variations, and gene expression patterns, including atypical, classical, basal, and mesenchymal subtypes [26].

These molecular classifications have revealed clinically relevant differences in tumor behavior, prognosis, and potential therapeutic vulnerabilities. Subsequent clinical sequencing studies in recurrent and metastatic HNC populations further confirmed substantial molecular heterogeneity among tumors, emphasizing both the potential of genomic-guided therapy and the need for expanded molecular characterization of rare HNC subtypes [27]. Thus, tumor location alone is no longer sufficient to define disease biology or guide therapeutic decision-making (Figure 2).

4.2. Integration of multi-omics technologies in precision oncology

Precision oncology relies on the integration of multiple molecular platforms, including genomics, transcriptomics, microRNA profiling, liquid biopsy, and artificial intelligence-based analysis. Genomic and transcriptomic approaches provide information regarding mutations, gene expression patterns, and molecular alterations associated with tumor initiation and progression. In contrast, microRNAs contribute an additional regulatory layer by controlling gene expression and influencing processes such as proliferation, apoptosis, invasion, and therapy resistance. Several dysregulated microRNAs, including miR-21, miR-375, miR-34a, miR-200 family members, miR-31, miR-155, and let-7 family members, have been investigated as diagnostic, prognostic, and predictive biomarkers in HNC, supporting their potential application in patient stratification and treatment monitoring [28].

Liquid biopsy approaches further enhance personalized medicine by enabling minimally invasive detection of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicle-associated molecular markers. These approaches provide dynamic information regarding tumor evolution, treatment response, and emerging resistance mechanisms, offering advantages over repeated tissue biopsies, particularly in anatomically complex head and neck tumors [29].

Artificial intelligence (AI) and machine learning approaches provide additional analytical capabilities by identifying complex molecular and clinical patterns that may not be detected using conventional statistical methods. AI-based models are increasingly being applied for risk prediction, treatment response assessment, imaging analysis, and integration of multi-dimensional cancer datasets, supporting more accurate patient-specific decision-making [30].

4.3. Targeting the tumor microenvironment

Although molecular profiling has improved tumor classification, increasing evidence indicates that cancer cells cannot be considered independently from their surrounding microenvironment. The tumor microenvironment (TME) consists of

cancer-associated fibroblasts, tumor-associated macrophages, myeloid-derived suppressor cells, endothelial cells, immune infiltrates, and extracellular matrix components that collectively regulate tumor growth, invasion, immune escape, and treatment resistance.

In HNSCC, interactions between tumor cells and stromal components promote epithelial–mesenchymal transition (EMT), angiogenesis, immune suppression, metastatic progression, and therapeutic resistance [31]. Consequently, therapies targeting only malignant cells may be insufficient because the supporting ecosystem remains intact. Emerging therapeutic strategies therefore aim to simultaneously disrupt tumor-intrinsic pathways and microenvironmental interactions to achieve more durable responses [31]. This concept represents a major shift in therapeutic thinking: the functional target of treatment is no longer the isolated tumor cell but the entire tumor ecosystem, including cellular interactions, signaling networks, and immune context.

4.4. Personalized medicine

Precision oncology represents a transition from statistical treatment strategies toward individualized biological models of cancer. Molecular classification systems such as TCGA have demonstrated that tumors originating from the same anatomical region may possess distinct biological identities requiring different therapeutic approaches [26]. Clinical sequencing studies have further established the feasibility of incorporating molecular information into treatment decisions, particularly in advanced and treatment-resistant disease settings [27]. Integration of molecular biomarkers, liquid biopsy, artificial intelligence, and tumor ecosystem analysis enables continuous monitoring of tumor evolution and treatment adaptation. Therefore, personalized oncology in HNC is not limited to identifying genetic alterations but represents a comprehensive strategy that incorporates tumor genomics, regulatory networks, microenvironmental interactions, and patient-specific characteristics. The future of HNC management will increasingly depend on understanding the molecular and ecological signature of each individual tumor rather than relying solely on anatomical classification.



Figure 2. From conventional treatment to molecularly guided therapy

5. Future perspectives

The future of HNC management lies in integrating molecular innovation with human-centered clinical care. Precision oncology has demonstrated that effective cancer management requires more than identifying molecular alterations; it requires understanding how genetic, environmental, lifestyle, and patient-specific factors collectively influence disease susceptibility, treatment response, and survivorship outcomes. Thus, the future paradigm of HNC care will depend on combining advanced technologies with individualized therapeutic strategies and patient-centered decision-making.

5.1. Integrating molecular precision with patient-centered care

Precision medicine represents a transition from population-based treatment approaches toward strategies that consider individual genetic variability, environmental exposures, and lifestyle-related factors influencing disease development and therapeutic response [32]. In HNC, this approach is particularly important because tumors arising from similar anatomical sites may demonstrate distinct molecular profiles and clinical behaviors. Recent advances emphasize that improving precision oncology requires integration of molecular technologies, biomarker-guided therapies, and patient-centered approaches rather than relying exclusively on tumor characteristics [33].

Therefore, successful implementation of precision oncology requires balancing molecular information with patient preferences, functional outcomes, and quality-of-life considerations. The ultimate goal is not simply to identify the most effective treatment for a tumor but to determine the most appropriate treatment strategy for an individual patient.

5.2. Emerging therapeutic frontiers: Immunotherapy, nanotechnology, and regenerative medicine

Advances in immunotherapy have significantly transformed the therapeutic landscape of HNC. Immune checkpoint inhibitors targeting programmed death-1 (PD-1) pathways have demonstrated improved survival outcomes in recurrent and metastatic HNSCC. Clinical trials such as KEYNOTE-012 and CheckMate-141 established the effectiveness of pembrolizumab and nivolumab, respectively, leading to the incorporation of immune checkpoint blockade into standard treatment strategies for selected patients with advanced disease [34].

Nanotechnology represents another emerging approach by enabling simultaneous diagnosis and therapy through nanotheranostic platforms. Nanoparticles, including gold- and silicon-based systems, can facilitate targeted drug delivery, molecular imaging, and enhanced therapeutic responses while potentially reducing systemic toxicity. These approaches may improve early detection and treatment precision by enabling real-time monitoring and site-specific therapeutic delivery in HNC [35].

Regenerative medicine provides an additional dimension by addressing the functional and structural consequences of HNC treatment. Since the disease frequently affects anatomical regions responsible for speech, swallowing, breathing, and facial expression, regenerative approaches involving tissue engineering, stem cell-based therapies, and biomaterial-assisted reconstruction may provide future strategies for restoring damaged tissues and improving long-term quality of life [36].

5.3. Early detection and molecular surveillance

A major future direction in HNC management is the transition from reactive treatment toward early detection and preventive intervention. Circulating biomarkers, particularly circulating tumor DNA (ctDNA), have emerged as promising tools for detecting tumor-associated molecular alterations, monitoring treatment response, and identifying disease recurrence before clinical manifestation [37].

The anatomical characteristics of the head and neck region, including high vascular accessibility, may provide advantages for blood- and saliva-based molecular surveillance. Liquid biopsy approaches have demonstrated potential for improving early diagnosis, monitoring minimal residual disease, and guiding therapeutic decisions. Given that many HNC cases are diagnosed at advanced stages with poor outcomes, implementation of sensitive molecular detection strategies could significantly improve prognosis through earlier intervention [38]. This shift represents a fundamental change in cancer management, where surveillance and risk prediction may begin before symptomatic disease develops, enabling earlier therapeutic intervention and potentially reducing disease-associated mortality.

5.4. Ethical integration of emerging technologies in future cancer care

Although technological advances provide unprecedented opportunities, their clinical success depends on ethical integration and meaningful patient engagement. Molecular profiling, liquid biopsy, artificial intelligence, and nanotechnology must be incorporated within frameworks that respect patient autonomy, informed decision-making, and individual treatment goals. Effective communication between clinicians and patients remains essential, particularly when discussing complex molecular information, uncertain predictions, and emerging therapeutic options. Current evidence highlights the need for structured approaches that integrate scientific information with patient values and expectations during treatment planning [39]. Similarly, although liquid biopsy and other molecular technologies demonstrate significant potential, further prospective validation and regulatory integration are required before widespread clinical implementation [40, 41, 42, 43]. Future progress will depend on establishing clinically validated biomarkers, incorporating evidence-based guidelines, and ensuring equitable access to advanced diagnostic and therapeutic technologies. Ultimately, the future of HNC medicine will not be determined solely by technological advancement but by the ability to apply these innovations in a manner that preserves patient dignity, communication, and quality of life. The next generation of cancer care will therefore represent a balance between molecular precision, ethical responsibility, and compassionate clinical practice.

6. Conclusion

HNC represents a disease in which biological complexity and human experience are inseparably connected. The progression of HNC is not simply the consequence of uncontrolled cellular proliferation but the result of continuous interactions among genetic alterations, epigenetic reprogramming, evolutionary selection, and the surrounding tumor ecosystem. Understanding cancer as an adaptive biological system provides a more comprehensive explanation for tumor heterogeneity, invasion, metastasis, and therapeutic resistance. Beyond molecular abnormalities, HNC uniquely challenges the physical and psychological identity of patients because it affects the structures responsible for speech, swallowing, appearance, and social communication. Therefore, successful treatment cannot be measured exclusively by tumor elimination or survival outcomes. Preservation of function, restoration of appearance, psychological adaptation, and patient-defined quality of life must become equally important components of cancer care. The emergence of precision oncology has transformed the landscape of HNC management by replacing generalized treatment strategies with molecularly informed approaches. Advances in genomics, transcriptomics, microRNA profiling, liquid biopsy, artificial intelligence, and tumor microenvironment analysis have created opportunities for more accurate diagnosis, treatment selection, and real-time monitoring. However, the future of HNC medicine will depend on integrating these technologies with ethical decision-making and individualized patient priorities. Future strategies combining immunotherapy,

nanotechnology, regenerative medicine, and early molecular detection have the potential to shift HNC care from late-stage intervention toward prevention, prediction, and personalized management. Nevertheless, technological advancement must remain guided by the fundamental purpose of medicine: improving human lives. The next era of head and neck oncology will therefore require a balance between molecular innovation and compassionate care, ensuring that advances in cancer science preserve not only survival but also identity, communication, dignity, and the overall human experience of every patient.

Reference

1. Alsahafi E, Begg K, Amelio I, Raulf N, Lucarelli P, Sauter T, Tavassoli M. Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death and Disease 2019;10:540–540. https://doi.org/10.1038/s41419-019-1769-9 .
2. Rothenberg SM, Ellisen LW. The molecular pathogenesis of head and neck squamous cell carcinoma. Journal of Clinical Investigation 2012;122:1951–7. https://doi.org/10.1172/jci59889 .
3. Rajkumar, C., Ramsridhar, S., Veeraraghavan, V. P., Francis, A. P., Mohideen, K., & Ali-Hassan, M. (2026). Network Predictions to Cellular Evidence: Exploring as a Multi-target Modulator in Head and neck squamous cell carcinoma. Journal of stomatology, oral and maxillofacial surgery, 102907. Advance online publication. https://doi.org/10.1016/j.jormas.2026.102907.
4. Albert, D., & Muthusekhar, M. R. (2026). Effectiveness of Topical Hemocoagulase on the Healing of Surgical Wounds in the Neck: A Randomized Clinical Trial. Journal of maxillofacial and oral surgery, 25(3), 895–902. https://doi.org/10.1007/s12663-025-02623-z.
5. Iftikhar A, Islam M, Shepherd S, Jones S, Ellis I. What is behind the lifestyle risk factors for head and neck cancer? Frontiers in Psychology 2022;13:960638–960638. https://doi.org/10.3389/fpsyg.2022.960638 .
6. Asiri, M., Zabebaha, H., Hussein, U. A., Adel, Z., Alkadir, O. K. A., Aldulaimi, A., Saeed, S. M., Taher, W. M., Alwan, M., Smerat, A., & Najafi, M. (2026). Cancer-associated fibroblasts as a target in head and neck squamous cell carcinoma: bridging mechanisms to therapy with drugs, adjuvants, and nanotechnology. Discover oncology, 10.1007/s12672-026-05450-x. Advance online publication. https://doi.org/10.1007/s12672-026-05450-x.
7. Baijens LWJ, Walshe M, Aaltonen L, Arens C, Cordier R, Cras P, Crevier-Buchman L, Curtis C, Golusiński W, Govender R, Eriksen JG, Hansen K, Heathcote K, Heß M, Hoşal Ş, Klußmann JP, Leemans CR, MacCarthy D, Manduchi B, Marie J-P, Nouraei SAR, Parkes C, Pflug C, Pilz W, Regan J, Rommel N, Schindler A, Schols AMWJ, Speyer R, Succo G, Wessel I, Willemsen ACH, Yılmaz T, Clavé P. European white paper: oropharyngeal dysphagia in head and neck cancer. European Archives of Oto-Rhino-Laryngology 2020;278:577–616. https://doi.org/10.1007/s00405-020-06507-5 .
8. Fingeret MC, Hutcheson KA, Jensen KS, Yuan Y, Urbauer DL, Lewin JS. Associations among speech, eating, and body image concerns for surgical patients with head and neck cancer. Head & Neck 2012;35:354–60. https://doi.org/10.1002/hed.22980 .
9. Kraus DH. Living in a Patient-Centric Universe. JAMA Otolaryngology–Head & Neck Surgery 2016;142:1231–1231. https://doi.org/10.1001/jamaoto.2016.3168 .
10. Goyal N, Day AT, Epstein JB, Goodman J, Graboyes EM, Jalisi S, Kiess AP, Ku JA, Miller MC, Panwar A, Patel VA, Sacco AG, Sandulache VC, Williams AM, Deschler DG, Farwell DG, Nathan CO, Fakhry C, Agrawal N. Head and neck cancer survivorship consensus statement from the American Head and Neck Society. Laryngoscope Investigative Otolaryngology 2021;7:70–92. https://doi.org/10.1002/lio2.702 .
11. Salk JJ, Fox E, Loeb LA. Mutational Heterogeneity in Human Cancers: Origin and Consequences. Annual Review of Pathology Mechanisms of Disease 2009;5:51–75. https://doi.org/10.1146/annurev-pathol-121808-102113 .
12. Pepper JW, Findlay CS, Kassen R, Spencer SL, Maley CC. SYNTHESIS: Cancer research meets evolutionary biology. Evolutionary Applications 2009;2:62–70. https://doi.org/10.1111/j.1752-4571.2008.00063.x .
13. Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discovery 2022;12:31–46. https://doi.org/10.1158/2159-8290.cd-21-1059 .
14. Bhat GhR, Sethi I, Sadida HQ, Rah B, Mir R, Algehainy NA, Albalawi IA, Masoodi T, Subbaraj GK, Jamal F, Singh M, Kumar R, Macha MA, Uddin S, Akil ASA-S, Haris M, Bhat AA. Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. Cancer and Metastasis Reviews 2024;43:197–228. https://doi.org/10.1007/s10555-024-10172-z .
15. Yuan S, Norgard RJ, Stanger BZ. Cellular Plasticity in Cancer. Cancer Discovery 2019;9:837–51. https://doi.org/10.1158/2159-8290.cd-19-0015 .
16. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012;481:306–13. https://doi.org/10.1038/nature10762 .
17. Luo W. Nasopharyngeal carcinoma ecology theory: cancer as multidimensional spatiotemporal “unity of ecology and evolution” pathological ecosystem. Theranostics 2023;13:1607–31. https://doi.org/10.7150/thno.82690 .
18. Costa EF, Nogueira TE, Lima NC de S, Mendonça EF, Leles CR. A qualitative study of the dimensions of patients’ perceptions of facial disfigurement after head and neck cancer surgery. Special Care in Dentistry 2013;34:114–21. https://doi.org/10.1111/scd.12039 .

19. Callahan C. Facial Disfigurement and Sense of Self in Head and Neck Cancer. Social Work in Health Care 2005;40:73–87. https://doi.org/10.1300/j010v40n02_05 .
20. Peng H, Chen S. Stigma and Its Influencing Factors in Patients with Head and Neck Cancer. Research Square 2023. https://doi.org/10.21203/rs.3.rs-3344803/v1 .
21. Řepová B, Zábrodský M, Plzák J, Kalfeřt D, Matoušek J, Betka J. Text-to-speech synthesis as an alternative communication means after total laryngectomy. Biomedical Papers 2020;165:192–7. https://doi.org/10.5507/bp.2020.016 .
22. McNeil BJ, Weichselbaum R, Pauker SG. Speech and Survival. New England Journal of Medicine 1981;305:982–7. https://doi.org/10.1056/nejm198110223051704 .
23. Otto RA, Lawrence VA, Dobie RA, Sakai C. Impact of a Laryngectomy on Quality of Life: Perspective of the Patient versus That of the Health Care Provider. Annals of Otology Rhinology & Laryngology 1997;106:693–9. https://doi.org/10.1177/000348949710600815 .
24. Teo I, Fronczyk K, Guindani M, Vannucci M, Ulfers SS, Hanasono MM, Fingeret MC. Salient body image concerns of patients with cancer undergoing head and neck reconstruction. Head & Neck 2016;38:1035–42. https://doi.org/10.1002/hed.24415 .
25. Threader J, McCormack L. Cancer-related trauma, stigma and growth: the 'lived' experience of head and neck cancer. European Journal of Cancer Care 2015;25:157–69. https://doi.org/10.1111/ecc.12320 .
26. Network TCGA. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517:576–82. https://doi.org/10.1038/nature14129 .
27. Morris LGT, Chandramohan R, West L, Zehir A, Chakravarty D, Pfister DG, Wong RJ, Lee NY, Sherman EJ, Baxi SS, Ganly I, Singh B, Shah JP, Shaha AR, Boyle JO, Patel SG, Roman BR, Barker CA, McBride SM, Chan TA, Doğan S, Hyman DM, Berger MF, Solit DB, Riaz N, Ho AL. The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers. JAMA Oncology 2016;3:244–244. https://doi.org/10.1001/jamaoncol.2016.1790 .
28. Thomaidou AC, Batsaki P, Adamaki M, Goulielmaki M, Baxevanis CN, Zoumpourlis V, Fortis SP. Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs. International Journal of Molecular Sciences 2022;23:8257–8257. https://doi.org/10.3390/ijms23158257 .
29. Nonaka T, Wong DT. Liquid Biopsy in Head and Neck Cancer: Promises and Challenges. Journal of Dental Research 2018;97:701–8. https://doi.org/10.1177/0022034518762071 .
30. Mahmood H, Shaban M, Rajpoot N, Khurram SA. Artificial Intelligence-based methods in head and neck cancer diagnosis: an overview. British Journal of Cancer 2021;124:1934–40. https://doi.org/10.1038/s41416-021-01386-x .
31. Bhat AA, Yousuf P, Wani NA, Rizwan A, Chauhan SS, Siddiqi MA, Bedognetti D, El-Rifai W, Frenneaux M, Batra SK, Haris M, Macha MA. Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy. Signal Transduction and Targeted Therapy 2021;6:12–12. https://doi.org/10.1038/s41392-020-00419-w .
32. Polverini PJ, D'Silva NJ, Lei YL. Precision Therapy of Head and Neck Squamous Cell Carcinoma. Journal of Dental Research 2018;97:614–21. https://doi.org/10.1177/0022034518769645 .
33. Havle E al. AbhayD. Precision Medicine in Head and Neck Cancer: Tailoring Therapies to Molecular Profiles. International Journal on Recent and Innovation Trends in Computing and Communication 2023;11:432–8. https://doi.org/10.17762/ijritcc.v11i7.9430 .
34. Mei Z, Huang J, Qiao B, Lam AK. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. International Journal of Oral Science 2020;12:16–16. https://doi.org/10.1038/s41368-020-0084-8 .
35. Chavda VP, Balar PC, Patel SB. Nanotheranostics-based Management of Head and Neck Cancer. Nanotheranostics 2023;7:202–9. https://doi.org/10.7150/ntno.81724 .
36. McPhail M, Janus JR, Lott DG. Advances in regenerative medicine for otolaryngology/head and neck surgery. BMJ 2020;369. https://doi.org/10.1136/bmj.m718 .
37. Bellairs JA, Hasina R, Agrawal N. Tumor DNA: an emerging biomarker in head and neck cancer. Cancer and Metastasis Reviews 2017;36:515–23. https://doi.org/10.1007/s10555-017-9685-x .
38. Aulakh SS, Silverman DA, Young K, Dennis SK, Birkeland AC. The Promise of Circulating Tumor DNA in Head and Neck Cancer. Cancers 2022;14:2968–2968. https://doi.org/10.3390/cancers14122968 .
39. Ahmed KH, Wilson T, Sharma A, Punjabi N, Inman JC. Ethical Considerations in Informed Consent: Contrasting Inpatient and Outpatient Laryngectomy Counseling. Otolaryngology 2025;173:1307–11. https://doi.org/10.1002/ohn.70005 .
40. Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. Journal of Hematology & Oncology 2022;15:131–131. https://doi.org/10.1186/s13045-022-01351-y .
41. Asiri, M., Zabebaha, H., Hussein, U. A., Adel, Z., Alkadir, O. K. A., Aldulaimi, A., Saeed, S. M., Taher, W. M., Alwan, M., Smerat, A., & Najafi, M. (2026). Cancer-associated fibroblasts as a target in head and neck squamous

cell carcinoma: bridging mechanisms to therapy with drugs, adjuvants, and nanotechnology. Discover oncology. https://doi.org/10.1007/s12672-026-05450-x
42. Kaarunya, S., Sinduja, P., Yuwanati, M., & Mullainathan, S. (2026). Significance of SLC1A5 expression in head and neck squamous cell carcinoma: A bioinformatics and in-vitro analysis. Journal of oral biology and craniofacial research, 16(3), 101448. https://doi.org/10.1016/j.jobcr.2026.101448
43. Padmanabhan, S., Sinduja, P., Yuwanati, M., Jayaraman, S., & Mullainathan, S. (2026). Tomatidine suppresses PI3K/Akt signaling to induce apoptosis in oral squamous cell carcinoma: An in vitro and molecular docking study. Journal of oral biology and craniofacial research, 16(1), 226–234. https://doi.org/10.1016/j.jobcr.2025.12.007